NCT02805894 is a Phase 1, PHASE2 clinical trial of NBTXR3 activated by IMRT only in Prostate Cancer, sponsored by Nanobiotix.

Who is sponsoring NCT02805894?

NCT02805894 is sponsored by Nanobiotix.

What drugs are being tested in NCT02805894?

Interventions in NCT02805894: NBTXR3 activated by IMRT only, NBTXR3 activated by Brachytherapy & IMRT.

What condition does NCT02805894 study?

NCT02805894 studies Prostate Cancer.

Is NCT02805894 still recruiting?

NCT02805894 is currently terminated. Last updated 10 May 2021.

Last reviewed 2021-05-10 · How we verify

NCT02805894

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma

Terminated Phase 1, PHASE2 Last updated 10 May 2021

What this trial tests

Phase 1, PHASE2 trial testing NBTXR3 activated by IMRT only in Prostate Cancer in 5 participants. Terminated before completion.

Timeline

15 November 2017

Primary endpoint
19 March 2020

19 March 2020

Quick facts

Lead sponsor	Nanobiotix
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	5
Start date	15 November 2017
Primary completion	19 March 2020
Estimated completion	19 March 2020
Sites	2 locations across United States

Drugs / interventions tested

NBTXR3 activated by IMRT only — full drug profile →
NBTXR3 activated by Brachytherapy & IMRT — full drug profile →

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Nanobiotix — full company profile →

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a Phase 1/2 open-label involving 2 groups of patients newly diagnosed with either unfavorable intermediate risk or high risk prostate adenocarcinoma. One group will receive only EBRT and the other group will receive a Brachytherapy boost and EBRT. Both groups will receive treatment with androgen deprivation. There will be 2 consecutive steps, a dose escalation and a subsequent dose expansion part.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Nanoparticles in the clinic: An update.
Anselmo AC, Mitragotri S. · · 2019 · cited 976× · PMID 31572799 · DOI 10.1002/btm2.10143
Application of Radiosensitizers in Cancer Radiotherapy.
Gong L, Zhang Y, Liu C, Zhang M, et al · · 2021 · cited 288× · PMID 33603370 · DOI 10.2147/ijn.s290438
Review on metal nanoparticles as nanocarriers: current challenges and perspectives in drug delivery systems.
Chandrakala V, Aruna V, Angajala G. · · 2022 · cited 286× · PMID 35005431 · DOI 10.1007/s42247-021-00335-x
Metal-based <i>NanoEnhancers</i> for Future Radiotherapy: Radiosensitizing and Synergistic Effects on Tumor Cells.
Liu Y, Zhang P, Li F, Jin X, et al · · 2018 · cited 184× · PMID 29556359 · DOI 10.7150/thno.22172
The evolution of brachytherapy for prostate cancer.
Zaorsky NG, Davis BJ, Nguyen PL, Showalter TN, et al · · 2017 · cited 117× · PMID 28664931 · DOI 10.1038/nrurol.2017.76
Current Trends in Cancer Nanotheranostics: Metallic, Polymeric, and Lipid-Based Systems.
Silva CO, Pinho JO, Lopes JM, Almeida AJ, et al · · 2019 · cited 101× · PMID 30625999 · DOI 10.3390/pharmaceutics11010022
Recent Trends of the Bio-Inspired Nanoparticles in Cancer Theranostics.
Madamsetty VS, Mukherjee A, Mukherjee S. · · 2019 · cited 82× · PMID 31708785 · DOI 10.3389/fphar.2019.01264
Engineering nanoparticles to reprogram radiotherapy and immunotherapy: recent advances and future challenges.
Jin J, Zhao Q. · · 2020 · cited 53× · PMID 32408880 · DOI 10.1186/s12951-020-00629-y

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Nanobiotix trials

Trials by the same sponsor.

NCT03589339 — NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy · Phase 1 · active not recruiting
NCT02721056 — NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers · Phase 1, PHASE2 · terminated
NCT02379845 — NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarc · Phase 2, PHASE3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02805894 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanobiotix
Last refreshed: 10 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02805894.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing